Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules
Overview
Authors
Affiliations
Increasing evidence suggests that therapy targeting the human epidermal growth factor receptor 3 (HER3) could be a viable route for targeted cancer therapy. Here, we studied a novel drug conjugate, Z-ABD-mcDM1, consisting of a HER3-targeting affibody molecule, coupled to the cytotoxic tubulin polymerization inhibitor DM1, and an albumin-binding domain for in vivo half-life extension. Z-ABD-mcDM1 showed a strong affinity to the extracellular domain of HER3 (K 6 nM), and an even stronger affinity (K 0.2 nM) to the HER3-overexpressing pancreatic carcinoma cell line, BxPC-3. The drug conjugate showed a potent cytotoxic effect on BxPC-3 cells with an IC value of 7 nM. Evaluation of a radiolabeled version, [Tc]Tc-Z-ABD-mcDM1, showed a relatively high rate of internalization, with a 27% internalized fraction after 8 h. Further in vivo evaluation showed that it could target BxPC-3 (pancreatic carcinoma) and DU145 (prostate carcinoma) xenografts in mice, with an uptake peaking at 6.3 ± 0.4% IA/g at 6 h post-injection for the BxPC-3 xenografts. The general biodistribution showed uptake in the liver, lung, salivary gland, stomach, and small intestine, organs known to express murine ErbB3 naturally. The results from the study show that Z-ABD-mcDM1 is a highly potent and selective drug conjugate with the ability to specifically target HER3 overexpressing cells. Further pre-clinical and clinical development is discussed.
Zhang J, Rinne S, Yin W, Leitao C, Bjorklund E, Abouzayed A ACS Pharmacol Transl Sci. 2024; 7(10):3228-3240.
PMID: 39416966 PMC: 11475273. DOI: 10.1021/acsptsci.4c00402.
Surface-engineered bacteria in drug development.
Leitao C, Stahl S, Lofblom J Microb Biotechnol. 2024; 17(10):e70033.
PMID: 39403960 PMC: 11474283. DOI: 10.1111/1751-7915.70033.
Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate.
Ma X, Wang M, Ying T, Wu Y Antib Ther. 2024; 7(2):114-122.
PMID: 38566971 PMC: 10983081. DOI: 10.1093/abt/tbae005.
Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action.
Allison S Biomedicines. 2022; 10(8).
PMID: 35892667 PMC: 9332372. DOI: 10.3390/biomedicines10081767.